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ABSTRACT
Objective Recent studies have suggested an important
role of the B cell chemoattractant CXCL13 in acute
neuroborreliosis (NB). Our aim was to confirm the
diagnostic role of CXCL13 and to evaluate its relevance
as a therapy response and disease activity marker in NB.
Methods CXCL13 was measured in cerebrospinal fluid
(CSF) and serum of patients with NB (n¼28), systemic
borreliosis (SB, n¼9), GuillaineBarre´ syndrome (GBS,
n¼11), Bell’s palsy (BP, n¼19), other cranial nerve
palsies (CNP, n¼5), cephalgia (C, n¼20), bacterial CNS
infections (B-CNS-I, n¼16) and viral CNS infections (V-
CNS-I, n¼18). For follow-up studies, serial sample pairs
were evaluated from 25 patients with NB (n¼56), 11
with B-CNS-I (n¼25) and 14 with V-CNS-I (n¼36).
Results CSF-CXCL13 was significantly elevated in NB
compared with other neurological diseases (p<0.001).
Using receiver operating characteristic analysis, 337 ng/g
was determined as a cut-off with a sensitivity of 96.4%
and a specificity of 96.9%. Of all the parameters
investigated, CSF CXCL13 showed the fastest response
to antibiotic therapy, decreasing significantly (p¼0.008)
within 1 week. In untreated patients, CSF CXCL13 was
elevated in patients with a short duration of disease.
Borrelia burgdorferi antibody index showed no significant
(p¼0.356) change over follow-up.
Conclusions The study confirms the relevance of
CXCL13 as a diagnostic biomarker of NB and suggests
that CSF CXCL13 in NB is linked to duration of disease
and could be a marker of disease activity and response
to antibiotic therapy.
INTRODUCTION
Neuroborreliosis (NB) is a nervous system mani-
festation of Lyme borreliosis, caused by the tick-
borne spirochete Borrelia burgdorferi (BB).1e4 Due to
a great variety of neurological symptoms such as
meningitis, meningoradiculitis or cranial nerve
palsies,5 6 identification of neuroborreliosis
frequently is a diagnostic challenge in clinical
neurology. Currently the method of choice for the
diagnosis of acute NB is the combined analysis of
basic cerebrospinal fluid (CSF) parameters
(lymphocytic pleocytosis, intrathecal synthesis of
immunoglobulins and/or bloodeCSF barrier
dysfunction) and determination of BB-specific
antibody index (BB-AI $1.5, ie, intrathecal anti-
body synthesis to BB).7 However, this approach has
important limitations. First, elevated basic CSF
variables are also found in various other inflam-
matory diseases of the central nervous system
(CNS).8 9 Second, intrathecal BB antibody
synthesis may not be detectable in early stages of
disease, especially if the disease duration is less than
2e3 weeks.10e14 Third, elevated BB-AI does not
discriminate between active and past infections, as
it is known to persist for years in spite of successful
treatment.14 Fourth, false-positive results may
occur due to antibody cross-reactivities.10 15 16
Fifth, due to the use of different isolates as antigen
in various immunosorbent assays for BB antibodies,
results may vary considerably among different
laboratories.
Recent studies have suggested an important role
of CXCL13 in the diagnosis of NB.17 18 CXCL13
belongs to the CXC chemokine family and is
a selective chemoattractant for B lymphocytes and
B-helper T cells via the chemokine receptor
CXCR5.19 Our aim was to confirm the diagnostic
value of CXCL13 in NB in comparison with
established diagnostic parameters such as BB-AI
and to evaluate the relevance of CXCL13 as
a marker of disease activity and therapy response in
acute NB.
METHODS
Patients
Drawing of blood and lumbar puncture was
performed for diagnostic purposes after the
patient’s informed consent was obtained. Paired
CSF and serum samples were collected between
January 2000 and September 2008 from 126
patients admitted to the Department of Neurology,
University of Ulm, Germany (for demographic
data, see table 1). Patients included 28 patients with
definite neuroborreliosis (NB), according to criteria
by Kaiser,7 and nine patients with systemic borre-
liosis (SB) who showed no clinical signs of neuro-
borreliosis and showed normal basic CSF findings
(including cell count, total protein and lactate). At
the time of lumbar puncture, none of the NB
patients received any antibiotic therapy. Further-
more, we included 69 patients with neurological
diseases relevant in the differential diagnosis of NB,
comprising 16 patients with bacterial infections of
the CNS (B-CNS-D, including meningitis or
meningoencephalitis caused by Treponema pallidum,
Mycobacterium tuberculosis, Streptococcus pneumoniae,
Meningococcus, Listeria monocytogenes, Haemophilus
influenzae, Staphylococcus aureus or other Strepto-
cocci), 18 patients with viral CNS diseases (V-CNS-
D, including meningitis or meningoencephalitis
caused by herpes simplex virus(HSV), varicella zoster
virus(VZV), EpsteineBarr virus(EBV), rubella virus,
tickborne encephalitis virus(TBEV), enterovirus), 11
patients with GuillaineBarré syndrome (GBS), 19
patients with Bell’s palsy (BP) and five patients
with other cranial nerve palsies (CNP). As normal
controls, we included 20 patients with cephalgia
(C) who presented with tension-type headache and
showed no evidence of a structural, haemorrhagic
or inflammatory lesion.
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For follow-up studies, we included serial CSF/serum sample
pairs from 25 patients with NB (n¼56), 11 patients with
bacterial (n¼25) and 14 patients with viral (n¼36) infections of
the CNS. Samples of eight of these NB patients were obtained
from the Department of Neurology, Ludwig-Maximilians
University, Munich, Germany. Standard antibiotic therapy of
NB patients consisted of ceftriaxone 2 g intravenously per day
over 2 weeks.
CSF analysis and CXCL13 assay
All CSF samples were stored at 808C until analysis. CSF
leucocyte count (cells/mm3), total protein (g/l), lactate (mmol/
l), CSF/serum albumin concentration ratio (Qalb), immuno-
globulin (Ig) G, A and M and oligoclonal IgG bands (OCB) were
obtained as previously described.20 Intrathecal synthesis of
antibodies to BB was determined by calculation of the specific
antibody indices (AI): AI¼QIg[spec]/QIg[total], if QIg[total]<
Qlim, and AI=QIg[spec]/Qlim, if QIg[total]>Qlim.21 The upper
reference range of QIg[total], Qlim, was calculated according to
Reiber ’s formula. AI values $1.5 were considered to be indica-
tive of intrathecal Ig synthesis against BB.21
CXCL13 was measured by quantitative enzyme-linked
immunosorbent assay (ELISA) (Quantikine; R&D Systems,
Minneapolis, Minnesota) according to the instructions supplied
by the manufacturer. For validating and assessing assay accuracy,
spike-and-recovery as well as linearity-of-dilution experiments
were performed. To compensate for differences in CSF protein
due to bloodeCSF barrier dysfunction in acute NB, CSF
CXCL13 was related to total CSF protein in accordance with
Rupprecht et al.17 The Borrelia afzelii+VIsE IgG ELISA (PKo
strain, Genzyme Virotech, Rüsselsheim, Germany) was used for
detection of IgG antibodies against BB sensu lato.
Statistical analysis
Statistical analysis was performed using SPSS (version 16.0;
SPSS, Chicago, Illinois). Differences in CXCL13 between groups
were analysed using KruskaleWallis test followed by single
pairwise comparisons (ManneWhitney U test). Wilcoxon
signed rank test was applied to compare concentrations at
individual time points with baseline (diagnostic LP) values, and
the Friedman test (repeated measures of ANOVA on ranks) was
applied to analyse repeated values for a global analysis of
progression. The correlation was analysed using the Spearman
rank order correlation. To test for normality, the Kolmogor-
oveSmirnov test was applied. Sensitivity was calculated as
(true-positive/(true-positive+false-negative)), specificity was
calculated as (true-negative/(true-negative+false-positive)). To
examine the accuracy of CXCL13 to differentiate NB from
controls, we used a receiver operating characteristic (ROC)
analysis, calculating the area under the ROC curve (AUROCC).
The Youden index was calculated for each cut-off value as
corresponding ((sensitivity+specificity)1) to find the cut-off
Figure 1 CXCL13 (ng/g protein) in the
cerebrospinal fluid (CSF) of
neuroborreliosis and other neurological
diseases; horizontal solid lines indicate
medians. KruskaleWallis test and
pairwise comparisons (ManneWhitney
U test) revealed a significant difference
between the groups (p<0.001). The
dashed line at 337 ng/g represents the
cut-off level yielding the highest
combined sensitivity and specificity for
discriminating patients with NB from
those with other diseases. A grey
triangle indicates an outlier
(neurosyphilis patient) with
cerebrospinal fluid CXCL13 of
113 000 ng/g. The y-axis is broken
twice. B-CNS-D, bacterial CNS disease;
BP, Bell’s palsy; C, cephalgia; CNP,
cranial nerve palsies; GBS,
GuillaineBarre´ syndrome; NB, definite
neuroborreliosis; SB, systemic borreliosis;
V-CNS-D, viral CNS disease.
Table 1 Demographic data and basic cerebrospinal fluid findings of patients included in this study
n (female/male) Age (years) Cell count (/ml)
Cerebrospinal fluid/serum
albumin concentration
ratio (310L3)
Intrathecal IgM
synthesis (%)
Oligoclonal IgG
bands (%)
Neuroborreliosis 28 (9/19) 58 (32 to 70) 84 (50 to 187) 13.8 (9.7 to 23.3) 78.6 85.7
Systemic borreliosis 9 (1/8) 44 (40 to 56) 1 (1 to 4) 6.6 (4.6 to 8.3) 22.2 11.1
Bacterial infections of the central nervous
system
16 (9/7) 53 (36 to 69) 2134 (117 to 4682) 58.1 (35.5 to 90.2) 18.8 13.3
Viral infections of the central nervous
system
18 (3/15) 38 (27 to 63) 178 (54 to 290) 11.8 (8.8 to 16.7) 16.7 22.2
Cephalgia 20 (10/10) 53 (44 to 64) 1 (0 to 2) 4.8 (3.7 to 7.1) 0 0
GuillaineBarre´ syndrome 11 (4/7) 40 (27 to 51) 1 (0 to 2) 17.4 (6.8 to 23.2) 9.1 63.6
Cranial nerve palsies 5 (1/4) 65 (54 to 66) 2 (1 to 2) 6.2 (5.7 to 8.4) 0 0
Bell’s palsy 19 (11/8) 40 (26 to 67) 2 (1 to 3) 5.2 (4.4 to 6.0) 0 15.8
Data are shown as the median and IQR.
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values which maximise discriminating accuracy.22 p Values
<0.05 were considered statistically significant.
RESULTS
Clinical findings and basic CSF examination results
At the time of diagnosis, the mean duration of symptoms in NB
patients was 11 days (median 7; range 1e40). Only 32.1% of
patients (nine of 28) remembered a tick bite. The most frequent
neurological symptoms in NB patients were polyradiculitis (nine
of 28) and facial nerve palsy (10 of 28). In CSF, all patients with
NB showed a lymphocytic pleocytosis, and most of the patients
(82%) revealed increased CSF protein measured by an elevation
of Qalb (table 1). Intrathecal IgM synthesis was found in 78%,
while IgG and IgA synthesis were observed in 35.7% (table 1).
All NB patients showed elevated BB-IgG-AI ($1.5), with
a median AI of 17 (range 2.6e104, table 1).
Assay validation
ELISA matrix spike recovery was acceptable, with an average
recovery of 100% and a range in spike recoveries of 93e109%
(n¼9). Linearity-of-dilution experiments showed an average
recovery of 102.5% (range 98e109; n¼6). According to linearity-
of-dilution experiments, concentrations <3.9 pg/ml were stated
as not detectable.
CXCL13 at diagnostic lumbar puncture
Patients with NB showed significantly elevated CSF CXCL13
levels as compared with all other groups (p¼0.001, figure 1). NB
patients with a shorter duration of disease (#8 days) showed
significantly higher CSF-CXCL13 concentrations as compared
with patients with a longer duration of disease (>8 days)
(pairwise comparison, p¼0.016; scatter plot, figure 2). Higher
CSF CXCL-13 concentrations in those patients tended to be
associated with a higher CSF leucocyte count (p¼0.095), though
this did not reach statistical significance. CSF-CXCL13 corre-
lated with neither Qalb (R¼0.350, p¼0.068) nor serum-CXCL13
(R¼0.372 p¼0.067). CSF CXCL13 levels were slightly elevated in
single cases of bacterial or viral CNS infections, with the highest
values being detected in patients with neurosyphilis (NS),
Staphylococcus aureus meningomyelitis and meningoencephalitis
caused by HSV (figure 1). CXCL13 was below the detection
limit in most patients with cephalgia, BP, CNP, GBS and patients
with SB (figure 1, table 1). Serum-CXCL13 was elevated in B-
CNS-D (inclusive NS) but was otherwise not significantly
different in NB as compared with controls (figure 3, table 1).
Highest serum-CXCL13 was observed in patients with pneu-
mococcal or Haemophilus influenza infections. The mean CXCL13
CSF/serum ratio in NB was 81.9, which was significantly higher
than in all other groups (p<0.001).
ROC analysis was performed to determine cut-off values of
CSF-CXCL13 for diagnosis of NB. To distinguish NB from all
other groups, the AUROCC was 0.98 (95% CI 0.953 to 1.004) for
Figure 2 Cerebrospinal fluid CXCL13
in neuroborreliosis patients prior to
therapy plotted against time since the
onset of symptoms (time to lumbar
puncture). The straight line is
a regression line; the correlation was
significant (p¼0.044, R¼0.383).
Figure 3 Serum CXCL13 (pg/ml) in bacterial CNS disease (B-CNS-D),
neuroborreliosis (NB) and other neurological diseases; KruskaleWallis
test p<0.001, pairwise comparisons (ManneWhitney U test) p<0.01;
for explanation of abbreviations, see figure 1.
Table 2 Accuracy of cerebrospinal fluid markers for diagnosis of
neuroborreliosis
Sensitivity Specificity
Basic cerebrospinal fluid findings 96.4 (82 to 100) 63.3 (53 to 73)
BB-AI 100 (88 to 100) 87.1 (70 to 97)
BB-AI+BCF 96.4 (82 to 100) 90.3 (74 to 98)
CXCL13: >337 ng/g 96.4 (82 to 100) 96.9 (91 to 99)
Sensitivity and specificity are shown as a percentage (95% CI in parentheses).
Basic cerebrospinal fluid findings (BCF)¼pleocytosis>4 cells, intrathecal IgM synthesis
and/or elevation of Qalb.
BB-AI is AI$1.5.
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CSF CXCL13. Using 337 ng/g as a cut-off, the sensitivity and
specificity were found to be 96.4 and 96.9% (table 2). The
diagnostic sensitivity and specificity of BB-IgG-AI were 100%
and 87.1%. Analysis of combined basic CSF variables (pleocy-
tosis, intrathecal synthesis of IgM and/or bloodeCSF barrier
dysfunction) showed a sensitivity of 96.4% and a specificity of
63.3% (table 2). Combination of pathological BB-AI and basic
CSF variables yielded a sensitivity of 96.4% and a specificity of
90.3% (table 2).
CSF-CXCL13 was elevated (>337 ng/g) in only three cases
with inflammatory CNS reaction not due to BB, including
a patient with neurosyphilis, Staphylococcus aureus meningo-
myelitis and HSV meningoencephalitis. Only in one patient
with NB was the CSF CXCL13 below 337 ng/g. BB-IgG-AI was
positive ($1.5) in four patients with diagnoses other than NB.
CXCL13 OVER FOLLOW-UP
Two weeks after onset of antibiotic therapy, 41% of NB patients
showed a complete remission of symptoms, 53% reported
subjective complaints such as pain or paraesthesia, and 6%
showed objective deficits such as persisting Bell’s palsy. CXCL13
showed a significant decrease within 1 week (p¼0.008) of onset
of antibiotic therapy (figure 4), with CSF CXCL13 levels
decreasing below the cut-off after 2 weeks. In contrast, the total
CSF leucocyte count decreased significantly (p¼0.009) only
during the second week after onset of antibiotic treatment,
though the CSF leucocyte count still remained above the normal
level (>4/ml) in all patients. BB-AI showed no significant
changes over follow-up (p¼0.356). Of all investigated parame-
ters, CXCL13 showed the fastest and most pronounced decrease
after onset of antibiotic therapy. In detail, CSF-CXCL13 fell
considerably in all 25 NB patients, whereas the CSF leucocyte
count (in 28%), albumin ratio (in 12%) and total protein (in
20%) showed even an increase in some patients.
As control groups, we analysed serial samples from patients
with bacterial (n¼11) and viral (n¼14) meningitis/meningoen-
cephalitis. CSF CXCL13 levels in bacterial infections of the CNS
showed no significant change over follow-up (p¼0.112), whereas
the CSF leucocyte count (in 81% of patients), albumin ratio (in
all) and lactate (in all) decreased. The CSF CXCL13 levels in viral
infections of the CNS showed also no significant change during
follow-up (p¼0.448), as did leucocyte count and Qalb. Serum
CXCL13 levels were similar to serum CXCL13 levels of controls.
DISCUSSION
CXCL13 as diagnostic marker in neuroborreliosis
We observed elevated CSF-CXCL13 in NB and neurosyphilis
(NS) as compared with other CNS diseases, which is in line with
previous studies.18 23 24 At a cut-off of 337 ng/g, CSF-CXCL13
revealed the highest combined sensitivity (96.4%) and specificity
(96.9%) for diagnosis of NB of all parameters investigated. Basic
CSF findings had an acceptable sensitivity (96.4%) but insuffi-
cient specificity (63.3%). Due to our selection criteria of patients
with NB, the sensitivity of BB-AI was 100%, but other studies
reported BB-AI to be negative in about 10e20% in the early
stages of disease activity (disease duration less than 2e3
weeks).10e14 Furthermore, these data revealed the specificity of
BB-AI to be comparatively low (87.1%), which may be due to
past infections with BB or antibody cross-reactivity with other
infectious agents such as Treponema pallidum. A combination of
BB-AI and basic CSF variables improved diagnostic accuracy in
accordance with previous studies10 but did not reach the diag-
nostic accuracy of CXCL13.
Elevated CSF-CXCL13 was observed in only three patients
with diagnosis other than NB: one patient was diagnosed as
HSV encephalitis, one was diagnosed as neurosyphilis, and one
suffered from Staphylococcus aureus meningoencephalitis. We
observed no correlation of CSF CXCL13 with either Qalb or
serum CXCL13, indicating that CSF CXCL13 is mainly
synthesised intrathecally.
Serum CXCL13 was not useful for diagnosis of NB but showed
elevated levels in patients with B-CNS-D. Consequently, serum-
CXCL13 could be useful to differentiate between NB and other
B-CNS-D, especially in the case ofNS,whichwas also observed to
show elevated CSF-CXCL13 concentrations.24 The pathophysi-
ological mechanisms underlying this discrepancy of CSF and
serum CXCL13 in NB are a matter of speculation. Immune
evasion strategies of BB in the blood compartment such as the
downregulation of outer surface proteins (Osp), hiding in extra-
cellular matrix or the secretion of complement-neutralising
proteins was suggested to reduce the immune response to BB in
the peripheral blood and consequently the production of CXCL13
bymonocytes and dendritic cells.25 Furthermore, migration of BB
into the CNS along peripheral nerves could also enable BB to
avoid the host immune system, resulting in low serum CXCL13
levels.25 26 In the nervous system, OspA has been observed to be
upregulated again, inducing the secretion of CXCL13 by inter-
action with the toll-like receptor 2 of monocytes.25
CXCL13 as a marker of disease activity and duration
Of all the parameters investigated, CSF CXCL13 showed the
fastest response to antibiotic therapy with intravenous
ceftriaxone, decreasing significantly within 1 week (figure 4). In
contrast, BB-AI showed no significant decrease under therapy,
which is in line with previous studies that found BB-AI to
persist up to several years after acute NB.10e14 Accordingly, BB-
AI could mimic acute inflammation with BB, especially in cases
of elevated cell count due to an infection with another pathogen.
The fast decline under therapy with ceftriaxone suggests that
CSF CXCL13 may offer a new tool to measure disease activity in
patients with NB. This is in line with a previous study that
reported a strong correlation between CXCL13 gene expression
and spirochetal load.27 However, we also observed high levels of
CSF CXCL13 to be related to a short duration of disease prior to
lumbar puncture, suggesting that CSF CXCL13 may be a marker
Figure 4 Relative changes (median and IQR) in cerebrospinal fluid
CXCL13, leucocyte count, Q (albumin) (CSF/serum albumin concentra-
tion ratio) and (Borrelia burgdorferi immunoglobulin G antibody index)
(BB-IgG-AI) over follow-up in 25 patients with neuroborreliosis.
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of disease duration in NB rather than a marker of disease
activity. Future studies including a larger number of patients
with follow-up data will have to clarify whether CXCL13 is
a marker of disease activity or merely a marker of disease
duration in NB.
CONCLUSION
Our study confirms the relevance of CXCL13 as a diagnostic
biomarker of NB. It suggests that CSF CXCL13 levels in NB are
linked to duration of disease and could be a marker of disease
activity and response to antibiotic therapy. We recommend CSF-
CXCL13 to be used for diagnosis of NB in addition to established
parameters such as BB-AI. Especially in cases with positive BB-
AI due to past NB and elevated CSF leucocyte count due to an
infection with another pathogen, CSF-CXCL13 is currently the
best tool to differentiate between active and past infection with
BB.
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doi:10.1136/jnnp.2009.195438corr1
M Senel, T A Rupprecht, H Tumani, et al.
The chemokine CXCL13 in acute
neuroborreliosis (J Neurol Neurosurg
Psychiatry 2010;81:929e933). Figures 1, 2
and 3 were inadvertently swapped around
during the production process. JNNP would
like to apologise to the authors for this
error. The correct order and legends are as
follows:
In the Results, under the heading CXCL13
at diagnostic lumbar puncture it should read:
“Patients with NB showed significantly
elevated CSF CXCL13 levels as compared
with all other groups (p<0.001, figure 1). NB
patients with a shorter duration of disease
(#8 days) showed significantly higher CSF-
CXCL13 concentrations as compared with
patients with a longer duration of disease
(>8 days) (pairwise comparison, p¼0.016;
scatter plot, figure 3). Higher CSF CXCL-13
concentrations in those patients tended to be
associated with a higher CSF leucocyte
count (p¼0.095), though this did not reach
statistical significance. CSF-CXCL13
correlated with neither Qalb (R¼0.350,
p¼0.068) nor serum-CXCL13 (R¼0.372
p¼0.067). CSF CXCL13 levels were slightly
elevated in single cases of bacterial or viral
CNS infections, with the highest values
being detected in patients with
neurosyphilis (NS), Staphylococcus aureus
meningomyelitis and meningoencephalitis
caused by HSV (figure 1). CXCL13 was
below the detection limit in most patients
with cephalgia, BP, CNP, GBS and patients
with SB (figure 1, table 1). Serum-CXCL13
was elevated in B-CNS-D (inclusive NS) but
was otherwise not significantly different in
NB as compared with controls (figure 2, table
1). Highest serum-CXCL13 was observed in
patients with pneumococcal or Haemophilus
influenza infections. The mean CXCL13 CSF/
serum ratio in NB was 81.9, which was
significantly higher than in all other groups
(p<0.001).
Figure 1 CXCL13 (ng/g protein) in the cerebrospinal fluid (CSF) of neuroborreliosis and other
neurological diseases; horizontal solid lines indicate medians. KruskaldWallis test and pairwise
comparisons (ManndWhitney U test) revealed a significant difference between the groups
(p<0.001). The dashed line at 337 ng/g represents the cut-off level yielding the highest combined
sensitivity and specificity for discriminating patients with NB from those with other diseases. A
grey triangle indicates an outlier (neurosyphilis patient) with cerebrospinal fluid CXCL13 of 113 000
ng/g. The y-axis is broken twice. B-CNS-D, bacterial CNS disease; BP, Bell’s palsy; C, cephalgia;
CNP, cranial nerve palsies; GBS, GuillaindBarre´ syndrome; NB, definite neuroborreliosis; SB,
systemic borreliosis; V-CNS-D, viral CNS disease.
Figure 2 Serum CXCL13 (pg/ml) in bacterial CNS disease (B-CNS-D), neuroborreliosis (NB) and
other neurological diseases; KruskaldWallis test p<0.001, pairwise comparisons
(ManndWhitney U test) p<0.01.
J Neurol Neurosurg Psychiatry October 2010 Vol 81 No 10 1177
PostScript
doi:10.1136/jnnp.2009.173732corr1
K Brantberg. Paroxysmal staccato tinnitus:
a carbamazepine responsive hyperactivity
dysfunction symptom of the eighth cranial
nerve J Neurol Neurosurg Psychiatry 2010;81:
451e455. A number of errors in the author ’s
manuscript were published uncorrected by
JNNP. In the first sentence of the
introduction “N VII” should have been
deleted. In the same section, fourth
paragraph, second to last sentence it should
be “fifth and seventh cranial nerves” rather
than “fifth and eigth cranial nerves”. In the
Discussion, in both the second and fourth
paragraph it refers to the fifth and seventh
cranial nerves when it should have been the
seventh and eigth cranial nerves. JNNP
would like to apologise for not correcting
these errors which occurred during editing
and which were also pointed out by the
author before publication.
doi:10.1136/jnnp.2009.178863corr1
D Wade. Measuring case complexity in
neurological rehabilitation. J Neurol
Neurosurg Psychiatry 2010;81:127. The
commentary by Derick Wade contained
several errors that need correction.
Column 1, paragraph 2: The RCS has four
components (not three).
Column 2, paragraphs 1 and 2: The RCS
can be completed after a single assessment,
and does not require two weeks as an
inpatient. It can be completed either
prospectively to record rehabilitation ‘needs’
or retrospectively to describe the level of
interventions actually provided. In the
analysis reported by Turner-Stokes et al
(J Neurol Neurosurg Psychiatry 2010;81:
146e153), it was used retrospectively.
Professor Wade therefore wishes to
withdraw the statement in paragraph 2:
“There are two other reasons for being concerned
about this scale. The first is practical. It cannot
help determine ‘complexity’ before patients are
admitted, yet this is the primary need of most
services, and most data are subjective, which
reduces its credibility with purchasers.”
Column 3, last paragraph should be
amended to read: “Nonetheless, the
Rehabilitation Complexity Scale is a simple,
clinical measure of overall resource use. Provided
its limitations are recognised, it may prove
useful.”
In addition, Professor Wade overlooked
a potential competing interest; although he
was not directly involved in the analysis
by Turner-Stokes et al (pp 146e153), he is a
member of the same academic department
(Department of Palliative Care Policy and
Rehabilitation, Kings College, London). He is
also a co-investigator in the NIHR-funded
Programme under which the RCS and
other tools to address complexity of
rehabilitation needs and interventions are
being developed.
In writing this commentary, Professor
Wade sought to highlight some of the
limitations of a tool that is necessarily
simplified for practical utility and to place
it in the context of the broader issues
involved in assessing case complexity in
rehabilitation, which are also being
addressed in other sections of the
programme. His critical appraisal of the
RCS and failure to declare his association
should not be taken in any sense to imply
disengagement from the programme. He
remains fully committed to this important
area of work.
Figure 3 Cerebrospinal fluid CXCL13 in neuroborreliosis patients prior to therapy plotted against
time since the onset of symptoms (time to lumbar puncture). The straight line is a regression line;
the correlation was significant (p¼0.044, R¼0.383).
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